EFFICACY OF HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY IN OVARIAN CANCER IN ADULT WOMEN (RS)

Main Article Content

Vanessa Isabel Abad Barahona
Flor Dalila Minchala Sucuzhañay
Dr. Andrés Felipe Mercado González
Dra. Carem Francelys Prieto Fuenmayor

Keywords

Chemotherapy, Efficacy, Hyperthermic, Intraperitoneal, Ovarian Cancer

Abstract

Context: In ovarian cancer, cytoreductive surgery is the treatment of choice, followed by adjuvant chemotherapy; where, hyperthermic intraperitoneal chemotherapy controls residual disease, with the combination of physical (thermal) and chemical (chemotherapeutic) methods prior to the formation of adhesions.


Objective: To determine the efficacy of hyperthermic intraperitoneal chemotherapy in ovarian cancer in adult women.


Procedures: Systematic review of primary studies published in PubMed, Scopus and Web of Science from 2013 to 2023, in Spanish and English.


Results: A total of 133,393 articles were obtained, 108 were selected after the first reading, later considering the inclusion and exclusion criteria, 9 studies were used for the present review. The categories hyperthermic intraperitoneal chemotherapy, Cytoreductive Surgery, Survival, Endothelial Ovarian Cancer are described.


Conclusion: Research results support the efficacy of HIPEC as a promising therapeutic approach for ovarian cancer treatment. , demonstranting an overall survival of 35 months and progression – free survival of 15.6 months.


 

Abstract 72 | pdf Downloads 29

References

1. Martínez-Ospina A, Porras-Ramírez A, Rico-Mendoza A. Epidemiology of ovarian cancer Colombia 2009 - 2016. Rev. chil. obstet. gynecol. [Internet]. 2019 Dec [cited 2023 May 31]; 84(6): 480-489. Available at: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-75262019000600480&lng=es. http://dx.doi.org/10.4067/S0717-75262019000600480.
2. World Health Organization. Cancer. In World Health Organization. [Internet]. 2023 Dec [cited 2023 May 30]. Available in: https://www.who.int/es/news-room/fact-sheets/detail/cancer.
3. González Fernández H, MoralesYera R, Santana Rodríguez S, Reinoso Padrón L, Heredia Martínez B. Clinical-epidemiological characterization of ovarian cancer. Rev. Finlay [Internet]. 2021 Dec [cited 2023 May 30]; 11(4): 359-370. Available at: http://scielo.sld.cu/scielo.php? script=sci_arttext&pid=S2221-24342021000400359&lng=es. Epub 2021-Dec-30.
4. International Agency for Research on Cancer. GLOBOCAN 2018: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2018[Internet]. Lyon: WHO; 2018[cited 2023 May 30]. Available in: https://gco.iarc.fr/
5. Cabezas López, E., De la Torre Sánchez-Montañez, I., San Frutos Llorente, L., García Espantaleón Navas, M., Giménez Alvira, L., Jiménez Garrido, M., Sánchez Turrión, V., & Pérez Medina, T. (2016). Cytoreductive surgery in advanced epithelial ovarian cancer. Advances in Obstetrics and Gynecology, 59(2), 60–65. https://doi.org/10.1016/j.pog.2015.07.006
6. Damián – Aucancela M, Cubillo – Chungata K, Basantes – Fuenmayor P, Ruiz – Ruiz M. Major advances in ovarian cancer clinical research: an updated review. Rev. Pole of Knowledge. [Internet]. 2022 Jan [cited 2023 May 30];7(1): 846-857. Available in: DOI: 10.23857/pc.v% vi%i.3514
7. Navarrete-Rengel M, Casares-Tamayo J, Espinoza De Los Monteros R. Overall survival and disease-free survival at five and ten years in patients with ovarian cancer: A single-center observational study. Rev. Oncol. Ecu. [Internet]. April 11, 2023 [cited May 30, 2023]; 33(1):49-57. Available in: https://www.roe-solca.ec/index.php/johs/article/view/673
8. Stewart C, Ralyea C, Lockwood S. Ovarian Cancer: An Integrated Review. Semin Oncol Nurs. 2019 Apr; 35(2):151-156. DOI: 10.1016/j.soncn.2019.02.001. Epub 2019 Mar 11. PMID: 30867104. Available at: https//doi.org/10.1016/j.soncn.2019.02.001
9. Javadi S, GaneshanDM, Qayyum A, Iyer RB, Bhosale P. Ovarian Cancer, the Revised FIGO Staging Sys-tem, and the Role of Imaging. AJR Am J Roentgenol. 2016 Jun; 206(6):1351-60. DOI: 10.2214/AJR.15.15199. Epub 2016 Apr 4. PMID: 27042752
10. O'Malley DM. New Therapies for Ovarian Cancer. J Natl Buy Canc Netw. 2019 May 1; 17(5.5):619-621. DOI: 10.6004/jnccn.2019.5018. PMID:31117037
11. Sugarbaker PH. It's what the surgeon doesn't see that kills the patient. J Nippon Méd Sch 2000; 67(1):5-8.
12. de Bree E, Romanos J, Tsiftsis DD. Hyperthermia in anticancer treatment. Eur J Surg Oncol 2002; 28(1):95.
13. Stewart C, Ralyea C, Lockwood S. Ovarian Cancer: An Integrated Review. Semin Oncol Nurs. 2019 Apr; 35(2):151-156. DOI: 10.1016/j.soncn.2019.02.001. Epub 2019 Mar 11. PMID: 30867104. Available at: https//doi.org/10.1016/j.soncn.2019.02.001
14. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170(4):974-9; Discussion 979-80.
15. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20(5):1248-59.
16. Astudillo J, López F, Lacerda A, Franca P, Martins B, Almeida R, Macedo S, Botrel S. Evaluation of morbidity and mortality and survival in patients with peritoneal carcinomatosis COE undergoing cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (HIPEC). 2023. Available in: https://www.scielo.br/j/rcbc/a/6mynLkfCcrbYB9r7vT93pCm/?lang=pt
17. Lim MC, Chang SK, Park B, Yoo HJ, Yoo CW, Nam BH, Park SY. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer. 2022. Available in: https://jamanetwork.com/journals/jamasurgery/fullarticle/2789724
18. Ghirardi V, De Feliceb F, D'Indinosante M, Bernardini F, Giudice MT, Fagotti A , Scambia G. Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary cytoreductive surgery in advanced epithelial ovarian cancer: is BRCA mutational status making a difference?. 2022. Available: https://www.sciencedirect.com/science/article/pii/S2468294222000107?via%3Dihub
19. Wang W, Gao M, Li X, Zheng H, Gao Y. Effect of neoadjuvant chemotherapy combined with intraperitoneal chemotherapy after tumor cell reduction at intervals on the prognosis of advanced epithelial ovarian cancer. 2022. Available at: 10.31083/j.ejgo4302030
20. Qi Y, Zhang Y, Shi Y, Yao S, Dai M, Cai H. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for HRR-mutated platinum-sensitive recurrent epithelial ovarian cancer: a phase III randomized clinical trial. 2022. Available in: http://doi.org/10.1177/15330338221104565
21. Zhang J, Li X, Ji Z, Ma R, Bai W, Li Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival with acceptable safety for advanced ovarian cancer: a clinical study of 100 patients. 2021. Available in: https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC8245244/
22. Costales A, Chambers L, Chichura A, Rose P, Mahdi H, Michener Ch, Yao M, Debernardo R. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer. 2021. Available in: http://doi.org/10.1016/ j.jogoh.2020.101844
23. Charo LM, Jou J, Binder P, Hohmann SF, Saenz Ch, McHale M, Eskander RN, Plaxe S. Management of peritoneal carcinomatosis with debulking plus intraoperative hyperthermic chemotherapy (HIPEC). 2020. Available in: https://revistas.fucsalud.edu.co/ index.php/ repertorio/article/view/910
24. Xu Z, Ge X, Zhang T, Shi Y, Sun M. Efficacy of neoadjuvant chemotherapy combined with intraperitoneal hyperthermic chemotherapy in advanced ovarian cancer. 2020. Available in: https://pubmed.ncbi.nlm.nih.gov/32521866/
25. Wu Q, Wu Q, Xu J, Cheng X, Wang X, Lu, Li X. Efficacy of hyperthermic intraperitoneal chemotherapy in patients with epithelial ovarian cancer: meta-analysis. 2019. Available in: https://doi.org/10.1080/02656736.2019.1612101
26. Saux OL, Decullier E, Freyer G, Glehen O, Bakrin N. Long-term survival in patients with epithelial ovarian cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). 2018. Available in: https://www.tandfonline.com/ doi/epdf/10.1080/ 02656736.2018.1518544?needAccess=true&role=button
27. Delotte J, Arias T, Guerin O, Boulahssass R, Bereder I, Bongain A, Benchimol D, Bereder JM. Hyperthermic intraperitoneal chemotherapy for the treatment of recurrent ovarian cancer in elderly women. 2015. Available in: https://obgyn.onlinelibrary.wiley. com/doi/10.1111/ aogs.12577
28. Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: systematic review and meta-analysis. 2015. Available in: https://doi.org/10.1016/j.ejso.2015.08.172
29. Votanopoulos KI, Newman NA, Russell G, Ihemelandu Ch, Shen P, Stewart JH, Levine EA.
30. Ovarian Cancer V.1.2021. NCCN Guidelines. [Internet]. 2020 Sep. [cited 2023 May 30]. Available at: https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendations/GetFileFromFileManager?fileManagerId=11868
31. Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020; 371:M3773.
32. Gallardo Rincón D, Alamilla García GC, Salcedo Hernández RA, Bahena González A, Álvarez Gómez RM, Arango Bravo EA, et al. Ovarian Cancer Oncoguide 2020. Lat Am J Clin Sci Med Technol. 2020 Nov; 2: 225-241.
33. Van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018; 378(3):230-40.
34. Bijelic L, Jonson A, Sugarbaker PH. Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol 2007; 18(12):1943-50.
35. van Driel WJ, Lok CA, Verwaal V, et al. The role of hyperthermic intraperitoneal intraoperative chemotherapy in ovarian cancer. Curr Treat Options Oncol 2015; 16(4):14.
36. Helm CW. Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer. Surg Oncol Clin N Am 2012; 21(4):645-63.
37. Cascales PA, Gil J, Galindo PJ, et al. Heterogeneity in patients and methods. A problem for hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 2019; 158(2):361-2.
38. Bijelic L, Jonson A, Sugarbaker PH. Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol 2007; 18(12):1943-50.
39. Chua TC, Robertson G, Liauw W, et al. Intraoperative hyperthermic intraperitoneal chemotherap and after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol 2009; 135(12):1637-45